ASH 2022: Brukinsa Bests Imbruvica In Leukemia/Lymphoma PFS
Adds To ORR Benefits Shown Earlier
Executive Summary
Two years after missing its primary endpoint in a different indication, BeiGene’s bet on a second Phase III head-to-head study with its BTK inhibitor Brukinsa have finally paid off, with PFS benefits demonstrated over rival Imbruvica.
You may also be interested in...
BeiGene’s Brukinsa Set To Take On Imbruvica With CLL Approval
The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.
China Approves Two More Home-Grown COVID-19 Antivirals
Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.